July 2016 Volume 12, Issue 7
Volume 12, Issue 7 | July 2016
July 2016
In this Issue
Discovery
Answers about alpha- synuclein
University of Pittsburgh team uncovers the cause of alpha-synuclein toxicity in Parkinson’sNext-generation mapping for genomic assemblies
Study published in Nature Methods describes use of BioNano Irys with Illumina-based NGS methodsBrain enzyme may protect against neurodegeneration
New study suggests correlation between NMNAT2 levels and diseaseAddressing the cause of schizophrenia
LDC and Boehringer Ingelheim team up to move beyond merely treating ‘positive symptoms’ of the diseaseIs depression a coordinated assault?
Study suggests depression is driven by networks of genes that span brain circuitsClinical Trials
One last study in LEMS
Catalyst inches closer to FDA approval for FirdapseAnswering an urgent need
Data on AbbVie SCLC antibody-drug conjugate are presented at ASCOChanging focus
Marinus Pharmaceuticals now concentrates on status epilepticus and pediatric orphan indicationsPhase 1 pass for APG101
Data shows APG101 decreases necessary transfusions in low to intermediate-1 risk transfusion-dependent MDS patientsAdamas steps up
Phase 2 study shows ADS-5102 offers improvement for MS patients with walking impairmentResearch & Development
Could microbiome research tool revolutionize drug development?
The University of Luxembourg announces ‘breakthrough’ HuMiX organ-on-a-chip model for the human gastrointestinal tractBaring the bones
New 3D constructs enable a closer look at cancer progression in bonesSmall entities; big implications
Seres enters into trio of strategic collaborations on infectious disease, immunologic disease and metabolic disease, with particular focus on microbiome researchThe impact of inflammation
Risk of autism linked to mother’s immune system dysfunction during pregnancyEditor's Focus
Exposing that murderous ole FDA
The 'FDA Death Meter' website is a great example of why people with an agenda and with minimal understanding of statistics should not be allowed anywhere near stats to make a pointCommentary
Out of order: The cost of a free market
Maybe it's time for the federal government to get into the business of funding (and perhaps even spearheading) antibiotic discovery and development, since this is an area where the free market seems to be falling shortNewly published PLOS paper calls for better sharing of genomic data
Better data sharing would improve research, providing benefits for patients, clinicians and researchersSpecial Reports
Special Report on Cell Biology: Sweetening the pot
Is improved understanding of glycobiology the secret to improved biologics?Q&A
Q&A: Small molecules and the cancer landscape
Dr. Thomas Dubensky, chief scientific officer at Aduro Biotech, talks about small-molecule therapeutics, immuno-oncology, the STING pathway and moreContract Services
Horizon, Ubiquigent partner with focus on ubiquitin
Ubiquitin modification plays key roles in homeostasis, cell signalingMoving on up
ClinTec adds offices in Spain, hires new managerMuScreen comes on scene
Crown launches platform to expand in-vivo efficacy research of immuno-oncology agentsPPD gains some recognition and a new face
PPD announced in June that it had been named best contract research organization in the Triangle Business Journal’s 2016 Life Sciences AwardsDiagnostics
The apnea connection
Study illuminates link between myocardial fibrosis and obstructive sleep apneaAn ally against colon cancer
Novigenix reports validation data on Colox blood test for colorectal cancerMyriad acquires Sividon Diagnostics
Move strengthens product portfolio with breast cancer prognostic test EndoPredictConfirmation for ConfirmMDx
Multicenter validation study indicates ConfirmMDx stratifies risk for aggressive prostate cancerBusiness & Government Policy
A medley of M&As
Though the ongoing Sanofi/Medivation struggle drags on, multimillion-dollar deals are still getting doneBrexit could mean big changes for EMA
In addition to challenges potentially facing UK-based companies in wake of electing to leave EU, Britons will likely lose EMA officeOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsFor your approval
A collection of recent regulatory approvals and other actions globallyPatent Docs: BIO International Convention Wrap-up
Kevin Noonan takes a look at intellectual property- and patent-related activity at the recent meeting of the Biotechnology Innovation OrganizationPreclinical
Forward momentum in Fragile X
Anavex reports positive preclinical results with ANAVEX 2-73 in Fragile XA compelling combination for TNBC
Bavituximab with an anti-PD-1 therapy causes tumor regression and improves survival, immune system activationA designer drug for breast cancer
Scripps scientists develop cancer-targeting drug that is a ‘clear breakthrough’ in precision medicineDepoVax vaccine may improve efficacy of checkpoint inhibitors
Data show control of cancer in advanced tumors previously non-responsive to PD-1 blockades aloneNatural killer cell therapy advancing toward first-in-human clinical trial
Fate Therapeutics Inc. presented data on its Adaptive NK Cell Therapy at the Innate Killer Summit 2016 in May in San Diego
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Journeying through cells' spatial dimensions
Spatial biology adds a new layer of knowledge to unsolved biological questions.
A Technology Guide for AI-Enabled Drug Discovery
Learn practical strategies for using artificial intelligence to find the best drug candidate.
Achieving bioanalytical precision and control
Advanced LIMS software helps researchers reliably manage complex bioanalytical workflows and data.
